Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

CA 19-9

Geisinger Epic Procedure Code:  LAB1911    Geisinger Epic ID:  19446

SPECIMEN COLLECTION
Specimen type: 

Serum (preferred) or plasma.


Preferred collection container: 
Alternate collection container: 
3 mL green/yellow-top (plasma separator) tube
Specimen required: 

1 mL serum or plasma; minimum 0.5 mL.


Special notes: 

Preferred specimen is serum in a 3.5 mL serum-separator tube. Plasma in a 3 mL plasma separator tube is also acceptable.



SPECIMEN PROCESSING
Processing instructions: 

Allow serum to clot. Centrifuge to separate serum or plasma within 2 hours of collection.


Transport temperature: 

Refrigerated (preferred). Frozen specimen also acceptable.


Specimen stability: 

Room temperature: 5 days. Refrigerated: 14 days. Frozen: 3 months.


Rejection criteria: 

Stability limits exceeded.



TEST DETAILS
Reference interval: 

< 35 U/mL.


Additional information: 

HAMA (Human Anti-Mouse Antibodies) interfere with this test. Patients who have been treated with mouse monoclonal antibodies should not be tested with this procedure.


CPT code(s):  86301
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

Cancer antigen 19-9.


Methodology: 
Roche Electrochemiluminescence Immunoassay. Patient results determined by assays using different manufacturers or methods may not be comparable.
Synonyms: 

CA1909, Cancer antigen 19-9


Clinical significance: 

A large percentage of patients wtih gastrointestinal tumors (such as pancreatic, liver, gastric, colorectal tumors) and some other malignancies have been shown to have elevated serum or plasma CA19-9 levels. CA19-9 levels may be useful for monitoring disease activity predicting relapse following treatment. CA19-9 should not be used as a screening test.


Doctoral Director(s): 
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM
Sheng-Ying (Margaret) Lo, PhD, DABCC
Review Date:  12/27/2024

Performing Locations